Blood pressure is a heritable determinant of cardiovascular disease (CVD) risk. Recent genome-wide association studies have identified several single-nucleotide polymorphisms (SNPs) associated with blood pressure, including rs1378942 in the c-Src tyrosine kinase (CSK) gene. Fish oil supplementation provides inconsistent protection from CVD, which may reflect genetic variation. We investigated the effect of rs1378942 genotype interaction with fish oil dosage on blood pressure measurements in the MARINA (Modulation of Atherosclerosis Risk by Increasing doses of N-3 fatty Acids) study, a parallel, double-blind, controlled trial in 367 participants randomly assigned to receive treatment with 0.45, 0.9, and 1.8 g/d eicosapentaenoic acid [EPA (20:5n-3)] and docosahexaenoic acid [DHA (22:6n-3)] (1.51:1) or an olive oil placebo for 12 mo. A total of 310 participants were genotyped. There were no significant associations with blood pressure measures at baseline; however, the interaction between genotype and treatment was a significant determinant of systolic blood pressure (SBP) (P = 0.010), diastolic blood pressure (DBP) (P = 0.037), and mean arterial blood pressure (MABP) (P = 0.014). After the 1.8 g/d dose, noncarriers of the rs1378942 variant allele showed significantly lower SBP (P = 0.010), DBP (P = 0.016), and MABP (P = 0.032) at follow-up, adjusted for baseline values, than did carriers. We found no evidence of SNP genotype association with endothelial function (brachial artery diameter and flow-mediated dilatation), arterial stiffness (carotid-femoral pulse wave velocity and digital volume pulse), and resting heart rate. A high intake of EPA and DHA could help protect noncarriers but not carriers of the risk allele. Dietary recommendations to reduce blood pressure in the general population may not necessarily benefit those most at risk. This trial was registered at controlled-trials.com as ISRCTN66664610.
Introduction
Blood pressure is affected by multiple genetic and environmental factors. Several genome-wide association studies have identified genetic variants associated with systolic blood pressure (SBP) 3 , diastolic blood pressure (DBP), and hypertension. Two studies, each in >25,000 individuals of European ancestry, originally identified 13 loci (1,2). The single-nucleotide polymorphism (SNP) rs1378942 in intron 1 of the c-Src tyrosine kinase gene (CSK) had the strongest association with DBP (0.43 mm Hg higher per minor allele; P = 1.0 3 10 223 ; n = 134,258) (1) . In a subsequent study in >200,000 individuals of European descent, 29 independent SNPs at 28 loci were significantly associated with SBP, DBP, or both (3) . For rs1378942, the increase in SBP per minor allele was 0.613 mm Hg (P = 5.7 3 10 223 ), the increase in DBP was 0.416 mm Hg (P = 2.7 3 10 226 ), and the increase in hypertension was 0.073 mm Hg (P = 1.0 3 10 28 ). The 28 loci were later confirmed in >120,000 Europeans (4). c-Src tyrosine kinase is a nonreceptor tyrosine protein kinase with roles in the regulation of cell growth, differentiation, and migration. Its involvement in the reorganization of the actin cytoskeleton in vitro (5) might indicate a role in control of blood pressure through an influence on Na-K ATPase activity (6) . CSK also mediates angiotensin II-dependent vascular smooth muscle cell proliferation (7, 8) .
Increases in SBP and DBP have a continuous gradual influence on risk of cardiovascular disease (CVD) and contribute to half of all cardiovascular deaths (9) . A prolonged increase in DBP of 5 mm Hg is associated with a 34% increase in risk of stroke and a 21% increase in risk of coronary events (10) . Reducing blood pressure has a major impact in reducing CVD risk. A reduction of 2 mm Hg in SBP has been estimated to confer reductions of 6% for stroke and 5% for coronary heart disease (9) .
Powerful cardioprotective effects of EPA (20:5n-3) and DHA (22:6n-3) in fish oil have been reported in human intervention trials (11, 12) . Although precise mechanisms of the beneficial effects are unclear, a number of potential processes, including the lowering of blood pressure, have been described (13) . However, some studies and meta-analyses have failed to demonstrate any significant protection from CVD risk by n-3 PUFA treatment (14) (15) (16) . Effects of fish oil on blood pressure are also inconsistent (see reference 17 for a recent review) and this may reflect genetic variation as well as different treatment conditions. The aim of the Modulation of Atherosclerosis Risk by Increasing doses of N-3 fatty Acids (MARINA) randomized controlled dietary intervention trial (18) was to investigate whether the recommended consumption of n-3 PUFAs equivalent to 1 portion of oily fish per week modified CVD risk factors in healthy individuals. In this study in 310 participants, we first tested the association of rs1378942 genotype with SBP, DBP, and mean arterial blood pressure (MABP) at baseline, as well as with potentially influential factors such as endothelial function, arterial stiffness, and resting heart rate at baseline. After randomly assigning participants to treatment with an olive oil placebo or EPA and DHA (1.51:1) at 0.45, 0.9, and 1.8 g/d for 12 mo, we first established significant interaction between rs1378942 SNP genotype and treatment as a determinant of phenotype and then investigated differences between genotype groups in response to supplements.
Participants and Methods
Participants. The MARINA trial was a single-center dietary intervention study with a randomized, double-blind, parallel design to test the effects of 3 daily doses of EPA and DHA on endothelial function and CVD risk factors (19) . The study was conducted at KingÕs College London between April 2008 and October 2010 and approved by the St. ThomasÕ Hospital National Health Service Research Ethics Committee (NREC 08/H0802/3). Written informed consent was given by participants, who were healthy nonsmoking men and women aged between 45 and 70 y, as described previously (19) . Participants with untreated high blood pressure or high cholesterol were excluded. One participant who was receiving stable medication for blood pressure and 2 treated for serum cholesterol (statins) were eligible but were not included in the genetic analysis. A total of 367 participants were randomly assigned to treatment. During an initial run-in period of 4 wk to baseline, participants consumed olive oil (British Pharmacopoeia specification) placebo capsules while restricting oily fish intake. Dietary intakes at baseline by randomly assigned treatment group were determined by an FFQ. The proportion of energy derived from total FAs, SFAs, and PUFAs was similar to that of the general population, as reported previously (19) . Capsules containing placebo or EPA and DHA (1.51:1) at 3 doses (0.45, 0.9, and 1.8 g/d) were supplied at regular intervals for 12 mo. Compliance was verified by assessment of EPA and DHA in erythrocyte phosphoglycerides at this time. The supply of oil blends and quality control analysis were provided by Croda Chemicals Europe Ltd. (Hull, UK) and encapsulation in gelatin was provided by Powerhealth (Pocklington, UK).
Measurement of blood pressure, arterial stiffness, endothelial function, and heart rate. Measurement of blood pressure, arterial stiffness and endothelial function were as described previously (19) . Full details of the measurement of heart rate were given previously (20) .
DNA extraction and SNP genotyping. DNA was extracted from buffy coats as described previously (21) . The SNP rs1378942 (A/C) is located in intron 1 of the CSK gene at position 75,077,367 on chromosome 15 (National Center for Biotechnology Information Genome Build 37.3, November 2012). Genotyping was performed by KBiosciences by using the KASPar system for the 310 participants who completed the study and for whom DNA was available. Genotype accuracy, as assessed by inclusion of duplicates in the array, was 98% and negative controls (water blanks) were included on each plate. The genotyping success rate was 89%.
Statistical analysis. SNP genotype distribution was tested for HardyWeinberg equilibrium by using a x 2 test with 1 df (P > 0.05) and did not deviate from expectations. Statistical analyses were carried out by using SPSS version 20.0 for Windows. Normal distribution of outcome variables was confirmed by Q-Q plots. Differences in quantitative variables between treatment groups at baseline were assessed by 1-factor ANCOVA. Due to the limited sample size, SNP genotype association analyses were based on a dominant inheritance model. Multivariate ANOVA was used to allow for multiple testing of genotype associations with measures of blood pressure, endothelial function, arterial stiffness, and heart rate. All P values were adjusted for the covariates BMI, age, gender, and ethnicity. The presence of any significant difference in SNP genotype frequencies between the 4 treatment groups was ascertained by x 2 test with 6 df (P > 0.05). Univariate ANCOVA was used to assess the interaction between genotypes and treatment. BMI, age, gender, and ethnicity were added to the model as covariates to adjust for possible confounding effects. All values presented in text and tables are expressed as means 6 SDs, or means (95% CIs). Significance was considered as P < 0.05.
Results
Characteristics of participants. Table 1 shows the characteristics of participants after a 4 wk run-in period with the olive oil placebo. Values are presented for the 310 participants of the 367 participants randomly assigned to treatment who completed the study. There were no significant differences in characteristics at baseline between the 310 participants with DNA available and the 57 without available DNA who were randomly assigned to treatment (data not shown). The number of participants allocated and drop-out rates did not differ significantly between treatment groups (19) . Women, mostly postmenopausal, outnumbered men by ;1.6:1, and ;20% of the sample was nonwhite, with similar proportions of Asian and black participants. The average BMI, >25 kg/m 2 , and mean waist circumferences (94 cm in men and 80 cm in women) were greater than the cutoffs, indicating risk of metabolic syndrome (19) .
CSK SNP allele and genotype frequencies. The allele frequencies of rs1378942 were as follows: A = 0.56; C = 0.44. Genotype frequencies were as follows: A/A = 0.34 (n = 102); A/C = 0.45 (n = 136); C/C = 0.22 (n = 66).
CSK SNP genotype associations with vascular variables at baseline. Table 2 shows measures of blood pressure, endothelial function, arterial stiffness, and resting heart rate after a 4-wk run-in period in participants who received a normal diet with olive oil placebo supplement, stratified by rs1378942 genotype. There were no significant associations between genotype and vascular phenotypes after adjustment for BMI, age, gender, and ethnicity (P > 0.05).
Interaction between CSK SNP genotype and treatment as a determinant of vascular variables. We previously reported no significant changes in vascular variables compared with baseline after treatment of MARINA participants with 0.45, 0.9, and 1.8 g/d EPA and DHA for 12 mo (19) . There were no significant differences in SNP genotype frequency between the treatment groups. Interaction between treatment and genotype was a significant determinant of SBP, DBP, and MABP but none of the other variables, as shown in Table 3 . Therefore, we examined the difference in blood pressure measures between the 2 genotype groups after olive oil placebo and each dose of EPA and DHA. A significant difference between noncarriers and carriers at follow-up adjusted for baseline values was seen only after the highest dose of 1.8 g/d EPA and DHA.
Discussion
We investigated the association of CSK rs1378942 A/C genotype with changes in blood pressure, endothelial function, arterial stiffness, and heart rate after dietary supplementation with the long-chain PUFAs EPA and DHA. There was no significant genotype association with any cardiovascular variable at baseline. Interaction between genotype and treatment was a significant determinant of SBP, DBP, and MABP. After treatment with the highest dose of EPA and DHA (1.8 g/d), the reductions in blood pressure variables compared with baseline were significantly greater in noncarriers of the minor C-allele than in carriers.
In genome-wide association studies, CSK rs1378942 was associated with ;0.4 mm Hg higher DBP per minor allele (1, 3) and ;0.6 mm Hg higher SBP (3). Each association explained only a very small proportion (;0.05-0.10%) of the total variation (1). The small effect of individual allelic variants showed that very large sample sizes are required for the detection of significant results; however, combined effects of multiple risk alleles on blood pressure can amount to increases of several millimeters of mercury (2) . There are no reported associations of rs1378942 with indices of endothelial function, arterial stiffness, or heart rate, which suggests that any association with blood pressure is not mediated by these factors. 1 Values are n (%) or means 6 SDs for participants randomly assigned to treatment groups and for whom DNA was available (n = 310).
Measurements made at baseline after a 4-wk run-in period with a normal diet including an olive oil placebo supplement are shown for each randomly assigned treatment group [placebo and EPA and DHA (1.51:1)] at the daily doses shown. BAD, brachial artery diameter; CVD, cardiovascular disease; DBP, diastolic blood pressure; DVP-RI, digital volume pulse resistance index; DVP-SI, digital volume pulse stiffness index; FMD, flow-mediated dilatation; HR, heart rate; MABP, mean arterial blood pressure; PWV c-f , pulse wave velocity (carotid-femoral); SBP, systolic blood pressure. CSK is one of a cluster of genes spanning ;72 kb on chromosome 15q24. c-Src tyrosine kinase phosphorylates tyrosine residues of Src-family kinases, resulting in an inactive conformation and suppression of signaling by various surface receptors. CSK represents a credible influence on blood pressure, because it is involved in reorganization of the actin cytoskeleton (5), which could affect Na-K ATPase activity (6) , and it mediates angiotensin II-dependent vascular smooth muscle cell proliferation (7, 8) . The rs1378942 genotype has been associated with blood pressure in a number of human studies (22) (23) (24) , but we found no significant effect in MARINA participants at baseline, most likely due to insufficient power. Rather than reflecting CSK action, rs1378942 might be a linkage disequilibrium (LD) marker of an adjacent functional site. Closest to CSK are the cytochrome P450 (CYP) enzyme genes CYP1A2 (;30 kb distant), CYPA1 (;60 kb), and CYP11A1 (;418 kb) as well as Unc-51-like kinase 3 (ULK3) (;46 kb). Cytochrome P450 enzymes are responsible for drug and xenobiotic chemical metabolism in the liver and cellular metabolism of arachidonic acid (20:4n26) derivatives (25) , some of which influence renal function, peripheral vascular tone, and blood pressure. CYP1A2 variants influence the level of gene expression and activity of the enzyme (26) . SNP rs762551 in an intron of CYP1A2, in moderate LD with CSK rs1378942 (r 2 = 0.63), has been found to influence caffeine metabolism (27) ; and CYP1A2 SNPs have been implicated in the influence of coffee intake on myocardial infarction at the daily doses shown for 12 mo. BAD, brachial artery diameter; CSK, c-Src tyrosine kinase; DBP, diastolic blood pressure; DVP-RI, digital volume pulse resistance index; DVP-SI, digital volume pulse stiffness index; FMD, flow-mediated dilatation; HR, heart rate; MABP, mean arterial blood pressure; PWV c-f , pulse wave velocity (carotid-femoral); SBP, systolic blood pressure; SNP, single-nucleotide polymorphism. 2 Interaction between genotype and treatment tested by univariate ANCOVA was a significant determinant of SBP, DBP, and MABP (P , 0.05).
NS is defined as P . 0.05. 3 Significance of difference in follow-up measure of each vascular variable corrected for baseline value between noncarriers (A/A) and carriers (A/C + C/C) of the risk allele tested by multivariate ANOVA. P values were adjusted for BMI, age, gender, ethnicity, and familial cardiovascular disease history. NS is defined as P . 0.05.
(28) and hypertension (29) . The CSK-ULK3 SNP rs6495122, which shows a positive association with blood pressure traits and hypertension (2) , is in strong LD with CSK rs1378942 (r 2 = 0.73). Both associations might be explained by the 2 SNPs tagging a single risk variant. ULK3 is a serine/threonine protein kinase. There are no suggestions that variation in this gene might affect blood pressure. Fine mapping and resequencing of the region will be required to identify any causal genetic variants.
The object of the MARINA study was to ascertain whether intakes of EPA and DHA at 0.45, 0.9, and 1.8 g/d affected predictors of CVD in healthy men and women at moderate risk. Intervention studies exploring the effects of fish oil on blood pressure have been carried out in both normotensive and hypertensive participants, and findings have been inconsistent in both groups. Four major meta-analyses of randomized controlled trials (17, (30) (31) (32) all found small, statistically significant reductions in both SBP (2-4 mm Hg) and DBP (2-2.5 mm Hg) among those with hypertension, but in normotensive individuals there were no significant effects. The use of refined olive oil as a placebo at doses as low as 3 g/d used in this study was regarded as neutral with regard to effects on blood lipids, blood pressure, or vascular function. We found no significant change compared with baseline in SBP, DBP, or MABP in the placebo group or with increasing intakes of EPA and DHA in predominantly normotensive MARINA participants after 12 mo (19) . Consistent effects on intermediate biomarkers of CVD risk are usually observed only at intakes >2 g/d, and even at these higher doses interindividual variability in response can be considerable (33) . This suggests that a range of gene variants may influence variability in pathophysiologic pathways contributing to CVD risk, which are influenced by changes in EPA and DHA availability.
Few studies have examined the effect of fish oils on cardiovascular phenotypes with respect to SNP genotype. Caron-Dorval et al. (34) studied n-3 PUFA-induced changes in CVD risk factors influenced by the peroxisome proliferator-activated receptor a (PPARa) gene L162V polymorphism. Supplementation with 5 g/d fish oil for 6 wk caused a significant decrease in DBP, but no significant genotype-by-diet interaction effect was observed. More recently, Armstrong et al. (35) studied the effects of fish oil supplementation of 5 g/d with respect to arachidonate 5-lipoxygenase (ALOX5) gene variants associated with a differential CVD risk in participants of African ancestry. There were no changes in plasma LDL-cholesterol concentration, heart rate, or blood pressure. HDL cholesterol and TGs varied by ALOX5 genotype in response to supplementation, but not in any way that conferred a consistent benefit to those at genetic risk.
The main strength of our study lies in the use of controlled doses of EPA and DHA over a 12-mo period, rather than estimates of n-3 PUFA consumption from FFQs or similar methods. Intake was verified by capsule counts, and long-term compliance was established by measurement of FAs in erythrocyte membranes. The main limitation was the relatively small sample of participants for post hoc genetic analysis, and the outcome should be viewed with caution. We used multivariate ANOVA to allow for multiple testing of genotype associations with phenotypes. A Bonferroni correction of the P value to take account of testing a single SNP and 9 vascular phenotypes would have removed the significance of difference in blood pressure measures between carriers and noncarriers at a threshold of P = 0.005. However, such correction is inappropriate because the vascular variables are not independent, but we concede that our results may be of marginal significance. The replication of the observed effects of treatment in larger genotype groups recruited prospectively would be needed to reliably confirm our results.
Differences in blood pressure between noncarriers and carriers of the CSK rs1378942 C-allele were significant only at the highest dose of 1.8 g/d EPA and DHA. Carriers putatively at risk of high blood pressure did not benefit from n-3 PUFA supplementation; in fact, reductions between 1 and 2 mm Hg were achieved with the olive oil placebo. Reductions of between 2 and 4 mm Hg imparting significant benefit as a primary preventive measure would accrue only to the 33% of the population not at potential risk. Our study, based on a single SNP, infers that dietary recommendations to reduce blood pressure in the general population may not necessarily benefit those who are most vulnerable. Risk scores based on the combined effect of multiple alleles on blood pressure account for increases of several millimeters of mercury (2,3), enough to have a significant impact on the risk of CVD and stroke (9) . Intervention trials powered to detect significant nutrient interactions with a panel of SNPs should eventually enable personalized dietary recommendations to reduce CVD risk on the basis of genotype.
